The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Propofol Injection for Operation General Anesthesia Market Research Report 2025
Synopsis
Propofol injection is used as an adjunct to spinal and epidural anesthesia, and it is used in conjunction with commonly used preoperative medications, neuromuscular blocking agents, inhaled anesthetics and analgesics, and no drug incompatibility has been encountered. It is used as a general anesthesia to complement regional anesthesia techniques, requiring lower doses. And often supplemental pain medication is required.
Global Propofol Injection for Operation General Anesthesia market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Propofol Injection for Operation General Anesthesia market research.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Propofol Injection for Operation General Anesthesia market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Aspen Pharma
Fresenius-Kabi
AbbVie
Baxter Healthcare
B.Braun
Maruishi
Piramal
Hikma Pharmaceuticals
AstraZeneca
Nhwa
Hengrui
Xi'an Libang
Yichang Humanwell
China National Medicines Guorui Pharmaceutical Co.,Ltd.
Segment by Specification
10ml
20ml
50ml
Others
Segment by Application
Hopitals
Clinics
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Propofol Injection for Operation General Anesthesia report covers below items:
Chapter 1: Product Basic Information (Definition, Specification and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Specification Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Propofol injection is used as an adjunct to spinal and epidural anesthesia, and it is used in conjunction with commonly used preoperative medications, neuromuscular blocking agents, inhaled anesthetics and analgesics, and no drug incompatibility has been encountered. It is used as a general anesthesia to complement regional anesthesia techniques, requiring lower doses. And often supplemental pain medication is required.
Global Propofol Injection for Operation General Anesthesia market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Propofol Injection for Operation General Anesthesia market research.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Propofol Injection for Operation General Anesthesia market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Aspen Pharma
Fresenius-Kabi
AbbVie
Baxter Healthcare
B.Braun
Maruishi
Piramal
Hikma Pharmaceuticals
AstraZeneca
Nhwa
Hengrui
Xi'an Libang
Yichang Humanwell
China National Medicines Guorui Pharmaceutical Co.,Ltd.
Segment by Specification
10ml
20ml
50ml
Others
Segment by Application
Hopitals
Clinics
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Propofol Injection for Operation General Anesthesia report covers below items:
Chapter 1: Product Basic Information (Definition, Specification and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Specification Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Index1 Propofol Injection for Operation General Anesthesia Market Overview
1.1 Product Overview and Scope of Propofol Injection for Operation General Anesthesia
1.2 Propofol Injection for Operation General Anesthesia Segment by Specification
1.2.1 Global Propofol Injection for Operation General Anesthesia Market Value Comparison by Specification (2023-2029)
1.2.2 10ml
1.2.3 20ml
1.2.4 50ml
1.2.5 Others
1.3 Propofol Injection for Operation General Anesthesia Segment by Application
1.3.1 Global Propofol Injection for Operation General Anesthesia Market Value by Application: (2023-2029)
1.3.2 Hopitals
1.3.3 Clinics
1.3.4 Others
1.4 Global Propofol Injection for Operation General Anesthesia Market Size Estimates and Forecasts
1.4.1 Global Propofol Injection for Operation General Anesthesia Revenue 2018-2029
1.4.2 Global Propofol Injection for Operation General Anesthesia Sales 2018-2029
1.4.3 Global Propofol Injection for Operation General Anesthesia Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Propofol Injection for Operation General Anesthesia Market Competition by Manufacturers
2.1 Global Propofol Injection for Operation General Anesthesia Sales Market Share by Manufacturers (2018-2023)
2.2 Global Propofol Injection for Operation General Anesthesia Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Propofol Injection for Operation General Anesthesia Average Price by Manufacturers (2018-2023)
2.4 Global Propofol Injection for Operation General Anesthesia Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Propofol Injection for Operation General Anesthesia, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Propofol Injection for Operation General Anesthesia, Product Type & Application
2.7 Propofol Injection for Operation General Anesthesia Market Competitive Situation and Trends
2.7.1 Propofol Injection for Operation General Anesthesia Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Propofol Injection for Operation General Anesthesia Players Market Share by Revenue
2.7.3 Global Propofol Injection for Operation General Anesthesia Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Propofol Injection for Operation General Anesthesia Retrospective Market Scenario by Region
3.1 Global Propofol Injection for Operation General Anesthesia Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Propofol Injection for Operation General Anesthesia Global Propofol Injection for Operation General Anesthesia Sales by Region: 2018-2029
3.2.1 Global Propofol Injection for Operation General Anesthesia Sales by Region: 2018-2023
3.2.2 Global Propofol Injection for Operation General Anesthesia Sales by Region: 2024-2029
3.3 Global Propofol Injection for Operation General Anesthesia Global Propofol Injection for Operation General Anesthesia Revenue by Region: 2018-2029
3.3.1 Global Propofol Injection for Operation General Anesthesia Revenue by Region: 2018-2023
3.3.2 Global Propofol Injection for Operation General Anesthesia Revenue by Region: 2024-2029
3.4 North America Propofol Injection for Operation General Anesthesia Market Facts & Figures by Country
3.4.1 North America Propofol Injection for Operation General Anesthesia Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Propofol Injection for Operation General Anesthesia Sales by Country (2018-2029)
3.4.3 North America Propofol Injection for Operation General Anesthesia Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Propofol Injection for Operation General Anesthesia Market Facts & Figures by Country
3.5.1 Europe Propofol Injection for Operation General Anesthesia Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Propofol Injection for Operation General Anesthesia Sales by Country (2018-2029)
3.5.3 Europe Propofol Injection for Operation General Anesthesia Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Propofol Injection for Operation General Anesthesia Market Facts & Figures by Country
3.6.1 Asia Pacific Propofol Injection for Operation General Anesthesia Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Propofol Injection for Operation General Anesthesia Sales by Country (2018-2029)
3.6.3 Asia Pacific Propofol Injection for Operation General Anesthesia Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Propofol Injection for Operation General Anesthesia Market Facts & Figures by Country
3.7.1 Latin America Propofol Injection for Operation General Anesthesia Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Propofol Injection for Operation General Anesthesia Sales by Country (2018-2029)
3.7.3 Latin America Propofol Injection for Operation General Anesthesia Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Propofol Injection for Operation General Anesthesia Market Facts & Figures by Country
3.8.1 Middle East and Africa Propofol Injection for Operation General Anesthesia Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Propofol Injection for Operation General Anesthesia Sales by Country (2018-2029)
3.8.3 Middle East and Africa Propofol Injection for Operation General Anesthesia Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Specification
4.1 Global Propofol Injection for Operation General Anesthesia Sales by Specification (2018-2029)
4.1.1 Global Propofol Injection for Operation General Anesthesia Sales by Specification (2018-2023)
4.1.2 Global Propofol Injection for Operation General Anesthesia Sales by Specification (2024-2029)
4.1.3 Global Propofol Injection for Operation General Anesthesia Sales Market Share by Specification (2018-2029)
4.2 Global Propofol Injection for Operation General Anesthesia Revenue by Specification (2018-2029)
4.2.1 Global Propofol Injection for Operation General Anesthesia Revenue by Specification (2018-2023)
4.2.2 Global Propofol Injection for Operation General Anesthesia Revenue by Specification (2024-2029)
4.2.3 Global Propofol Injection for Operation General Anesthesia Revenue Market Share by Specification (2018-2029)
4.3 Global Propofol Injection for Operation General Anesthesia Price by Specification (2018-2029)
5 Segment by Application
5.1 Global Propofol Injection for Operation General Anesthesia Sales by Application (2018-2029)
5.1.1 Global Propofol Injection for Operation General Anesthesia Sales by Application (2018-2023)
5.1.2 Global Propofol Injection for Operation General Anesthesia Sales by Application (2024-2029)
5.1.3 Global Propofol Injection for Operation General Anesthesia Sales Market Share by Application (2018-2029)
5.2 Global Propofol Injection for Operation General Anesthesia Revenue by Application (2018-2029)
5.2.1 Global Propofol Injection for Operation General Anesthesia Revenue by Application (2018-2023)
5.2.2 Global Propofol Injection for Operation General Anesthesia Revenue by Application (2024-2029)
5.2.3 Global Propofol Injection for Operation General Anesthesia Revenue Market Share by Application (2018-2029)
5.3 Global Propofol Injection for Operation General Anesthesia Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Aspen Pharma
6.1.1 Aspen Pharma Corporation Information
6.1.2 Aspen Pharma Description and Business Overview
6.1.3 Aspen Pharma Propofol Injection for Operation General Anesthesia Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Aspen Pharma Propofol Injection for Operation General Anesthesia Product Portfolio
6.1.5 Aspen Pharma Recent Developments/Updates
6.2 Fresenius-Kabi
6.2.1 Fresenius-Kabi Corporation Information
6.2.2 Fresenius-Kabi Description and Business Overview
6.2.3 Fresenius-Kabi Propofol Injection for Operation General Anesthesia Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Fresenius-Kabi Propofol Injection for Operation General Anesthesia Product Portfolio
6.2.5 Fresenius-Kabi Recent Developments/Updates
6.3 AbbVie
6.3.1 AbbVie Corporation Information
6.3.2 AbbVie Description and Business Overview
6.3.3 AbbVie Propofol Injection for Operation General Anesthesia Sales, Revenue and Gross Margin (2018-2023)
6.3.4 AbbVie Propofol Injection for Operation General Anesthesia Product Portfolio
6.3.5 AbbVie Recent Developments/Updates
6.4 Baxter Healthcare
6.4.1 Baxter Healthcare Corporation Information
6.4.2 Baxter Healthcare Description and Business Overview
6.4.3 Baxter Healthcare Propofol Injection for Operation General Anesthesia Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Baxter Healthcare Propofol Injection for Operation General Anesthesia Product Portfolio
6.4.5 Baxter Healthcare Recent Developments/Updates
6.5 B.Braun
6.5.1 B.Braun Corporation Information
6.5.2 B.Braun Description and Business Overview
6.5.3 B.Braun Propofol Injection for Operation General Anesthesia Sales, Revenue and Gross Margin (2018-2023)
6.5.4 B.Braun Propofol Injection for Operation General Anesthesia Product Portfolio
6.5.5 B.Braun Recent Developments/Updates
6.6 Maruishi
6.6.1 Maruishi Corporation Information
6.6.2 Maruishi Description and Business Overview
6.6.3 Maruishi Propofol Injection for Operation General Anesthesia Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Maruishi Propofol Injection for Operation General Anesthesia Product Portfolio
6.6.5 Maruishi Recent Developments/Updates
6.7 Piramal
6.6.1 Piramal Corporation Information
6.6.2 Piramal Description and Business Overview
6.6.3 Piramal Propofol Injection for Operation General Anesthesia Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Piramal Propofol Injection for Operation General Anesthesia Product Portfolio
6.7.5 Piramal Recent Developments/Updates
6.8 Hikma Pharmaceuticals
6.8.1 Hikma Pharmaceuticals Corporation Information
6.8.2 Hikma Pharmaceuticals Description and Business Overview
6.8.3 Hikma Pharmaceuticals Propofol Injection for Operation General Anesthesia Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Hikma Pharmaceuticals Propofol Injection for Operation General Anesthesia Product Portfolio
6.8.5 Hikma Pharmaceuticals Recent Developments/Updates
6.9 AstraZeneca
6.9.1 AstraZeneca Corporation Information
6.9.2 AstraZeneca Description and Business Overview
6.9.3 AstraZeneca Propofol Injection for Operation General Anesthesia Sales, Revenue and Gross Margin (2018-2023)
6.9.4 AstraZeneca Propofol Injection for Operation General Anesthesia Product Portfolio
6.9.5 AstraZeneca Recent Developments/Updates
6.10 Nhwa
6.10.1 Nhwa Corporation Information
6.10.2 Nhwa Description and Business Overview
6.10.3 Nhwa Propofol Injection for Operation General Anesthesia Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Nhwa Propofol Injection for Operation General Anesthesia Product Portfolio
6.10.5 Nhwa Recent Developments/Updates
6.11 Hengrui
6.11.1 Hengrui Corporation Information
6.11.2 Hengrui Propofol Injection for Operation General Anesthesia Description and Business Overview
6.11.3 Hengrui Propofol Injection for Operation General Anesthesia Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Hengrui Propofol Injection for Operation General Anesthesia Product Portfolio
6.11.5 Hengrui Recent Developments/Updates
6.12 Xi'an Libang
6.12.1 Xi'an Libang Corporation Information
6.12.2 Xi'an Libang Propofol Injection for Operation General Anesthesia Description and Business Overview
6.12.3 Xi'an Libang Propofol Injection for Operation General Anesthesia Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Xi'an Libang Propofol Injection for Operation General Anesthesia Product Portfolio
6.12.5 Xi'an Libang Recent Developments/Updates
6.13 Yichang Humanwell
6.13.1 Yichang Humanwell Corporation Information
6.13.2 Yichang Humanwell Propofol Injection for Operation General Anesthesia Description and Business Overview
6.13.3 Yichang Humanwell Propofol Injection for Operation General Anesthesia Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Yichang Humanwell Propofol Injection for Operation General Anesthesia Product Portfolio
6.13.5 Yichang Humanwell Recent Developments/Updates
6.14 China National Medicines Guorui Pharmaceutical Co.,Ltd.
6.14.1 China National Medicines Guorui Pharmaceutical Co.,Ltd. Corporation Information
6.14.2 China National Medicines Guorui Pharmaceutical Co.,Ltd. Propofol Injection for Operation General Anesthesia Description and Business Overview
6.14.3 China National Medicines Guorui Pharmaceutical Co.,Ltd. Propofol Injection for Operation General Anesthesia Sales, Revenue and Gross Margin (2018-2023)
6.14.4 China National Medicines Guorui Pharmaceutical Co.,Ltd. Propofol Injection for Operation General Anesthesia Product Portfolio
6.14.5 China National Medicines Guorui Pharmaceutical Co.,Ltd. Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Propofol Injection for Operation General Anesthesia Industry Chain Analysis
7.2 Propofol Injection for Operation General Anesthesia Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Propofol Injection for Operation General Anesthesia Production Mode & Process
7.4 Propofol Injection for Operation General Anesthesia Sales and Marketing
7.4.1 Propofol Injection for Operation General Anesthesia Sales Channels
7.4.2 Propofol Injection for Operation General Anesthesia Distributors
7.5 Propofol Injection for Operation General Anesthesia Customers
8 Propofol Injection for Operation General Anesthesia Market Dynamics
8.1 Propofol Injection for Operation General Anesthesia Industry Trends
8.2 Propofol Injection for Operation General Anesthesia Market Drivers
8.3 Propofol Injection for Operation General Anesthesia Market Challenges
8.4 Propofol Injection for Operation General Anesthesia Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
